Challenging Cases in Lung Cancer: Acquired Resistance to Tarceva (erlotinib) in A Previously Responding Advanced NSCLC Patient with an Activating EGFR Mutation

Dr. Robert Doebele
Assistant Professor, Medical Oncology
University of Colorado Medical Center
Denver, CO

Dr. Jyoti Patel
Associate Professor, Medical Oncology
Feinberg School of Medicine
Northwestern University
Chicago, IL
Additional Faculty

• Dr. Suresh Ramalingam, Emory University
• Dr. Jonathan Goldman, Premier Oncology
• Dr. Julie Brahmer, Johns Hopkins University
• Dr. Heather Wakelee, Stanford University
• Dr. Karen Reckamp, City of Hope Cancer Ctr

Small Resected NSCLC with Tiny Satellite Lesions: Adjuvant Therapy

• 73 year old Asian never-smoking man presents with metastatic lung adenocarcinoma
• Molecular testing at time of initial workup shows activating EGFR mutation
• Starts on first line Tarceva (erlotinib) and has an excellent response before gradual progression after 14 months
• What would you recommend next?
Dr. Robert Doebele  
Assistant Professor, Medical Oncology  
University of Colorado Medical Center  
Denver, CO

Dr. Jyoti Patel  
Associate Professor, Medical Oncology  
Feinberg School of Medicine  
Northwestern University  
Chicago, IL
Do you favor pursuing a repeat biopsy for patients who develop acquired resistance?
How would you use the results?

Dr. Suresh Ramalingam
Associate Professor, Medical Oncology
Winship Cancer Center
Emory University
Atlanta, GA
Dr. Jonathan Goldman  
Medical Oncologist  
Chair of Oncology Research  
Premier Oncology  
Santa Monica, CA

Dr. Julie Brahmer  
Associate Professor, Medical Oncology  
Sidney Kimmel Cancer Center  
Johns Hopkins University  
Baltimore, MD
Dr. Heather Wakelee  
Assistant Professor, Medical Oncology  
Stanford University Cancer Center  
Palo Alto, CA

Dr. Karen Reckamp  
Associate Professor, Medical Oncology  
City of Hope Cancer Center  
Duarte, CA